#HER2 DX and its impact on therapeutic decision-making
Understanding its credibility, and clinical relevance is crucial for optimizing treatment strategies and enhancing patient outcomes in the context of #HER2 + #breastcancer
👉🏻ow.ly/YbVo50RnSp6

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and TNBC: TROPION-PanTumor01 Study

🔍85 pts, heavily pretreated

HR+/HER2- and TNBC
ORR➡️27% and 32%
PFS➡️8.3 and 4.8 mo
OS➡️ NR and 13.5 mo

ILD➡️1 pts
No treatment-related deaths

OncoAlert
ascopubs.org/doi/10.1200/JC…

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin: METALLICA

🔍Normoglycemic pts (Cohort A) and prediabetic pts (B)

G3-4 HG (first 8 weeks)
Cohort A➡️2.1%
Cohort B➡️15%

Prophylactic metformin✅️

OncoAlert…

Curveball… So it turns out I have a new primary bc. It’s HER2+ (original bc is Er+). This could be why my liver hasn’t been responding to treatment, because it’s a different type. This could open up new lines of treatment. 🤞🏻 When did a cancer diagnosis become good news?! 😮🤞🏻

#HER2 is getting far more than just #BreastCancer
Are we witnessing a breakthrough in treating #HER2 #brain #metastases with novel antibody drug conjugates like #Enhertu ??
The whole story of #Enhertu #ADCs #HER2 incl #HER2 low #HER2 ultralow is getting far more interesting 👆…

Almost there! We're now in touching distance of 200,000 signatures on our #EnhertuEmergency petition.

Please continue spreading the word to help give women with HER2-low secondary breast cancer the hope of more time.

action.breastcancernow.org/enhertu-emerge…

Be sure to join Hochmair Maximilian next week, alongside Florian Lordick and our host Ilaria Colombo, to explore the latest clinical implications of #HER2 in #LungCancer 🫁

⏰ 30th April at 5PM CEST

Join and share your questions live ⬇️

Damn I want a Sugar Daddy but without the SUGAR😌😌

Er low Her2 negative breast cancer behave like TNBC. So should we give them IO like tnbc along with chemotherapy and endocrine therapy ? AnnalsSurgOncology Tessa Higgins Sara Tolaney Dr Sarah Sammons

#Enhertu is expanding 🚀
Well done Daiichi Sankyo EU Daiichi Sankyo US and fingers crossed for delivering great treatment opportunities to all #HER2 Patients

daiichisankyo.com/files/investor…

Researchers at King's College London investigated the effect of trastuzumab monotherapy and its combination with different HER2 🎯 targeting treatments in a panel of breast cancer cell lines and patient-derived #organoids .

📖 British Journal of Cancer | go.nature.com/3Q4ZBwa

The limbo of having ER/PR low (<10%) is currently a very important problem for trial enrollment #BCSM #MBC
ER 0 PR 5% HER2 0
1⃣cannot be enrolled in HR+ cohorts if have not received CDK4/6i
2⃣cannot be enrolled in TNBC cohort because ASCO/CAP guidelines
FDA Oncology relax I/E cr

That color soooo🔥🔥🥰

Antibody–drug conjugates are active in patients with HER2+ breast cancer brain metastases: where do we go from here? Read the editorial on the brain mets analysis from DB03 by Sarah Sammons (Dr Sarah Sammons) and Nancy Lin (@nlinmd) from Dana-Farber’s Breast Oncology Center. esmoopen.com/article/S2059-…

AZN focusing on HER2. Let’s see another deal beteeen AstraZeneca and Angle #AGL

HER2 score2 のFISHの陽性率って5-15%とかそんなもんだし、あんまショボいの取りすぎても全然来ないだよね。
逆にFISHでポジるやつって、免染の時点でFISHポジるやろ！てオーラ纏ってるしね。

I loved him when he looked like THIS🥰

Answer: according to a recent large study, over 80% of HER2-zero (IHC 0) breast cancers actually exhibit some staining, qualifying for being considered HER2-ultralow.
Ref: link.springer.com/content/pdf/10…

☑Testing for TROP-2 is not necessary when considering SG. TROP-2 is overexpressed across all #breastcancer subtypes but is most elevated in #TNBC . SG is the first and only FDA-approved TROP-2‒directed ADC in the HER2-negative #breastcancer setting.

Missed Aditya Bardia, MD 's Tweetorial on treating HER2-low mBC: 2L and beyond? No worries! It is now available on-demand: ow.ly/qBz250RiMSO

Explore patient case discussions covering ESR1 and PIK3CA co-mutations, TRAE management, and post-2L treatment options. Don't miss…